Sustained response to atogepant in episodic and chronic migraine: Post-hoc analyses of ELEVATE and PROGRESS, and their open-label extension
Cephalalgia · 2026-11 · 46 (11)
DOI: 10.1177/03331024261499722 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cephalalgia, online erschienen am 17.11.2026. Verfasst von Soo-Jin Cho und 10 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Background
These post-hoc analyses evaluated the proportions of participants who experienced sustained responses to atogepant, an oral calcitonin gene-related peptide receptor antagonist, over two 3-month, double-blind, randomized controlled trials (RCTs) (ELEVATE and PROGRESS) and a 12-month interim analysis of the open-label extension (OLE) study that was composed of participants from ELEVATE and PROGRESS.
Methods
Post-hoc analyses were conducted to assess the sustained responses with atogepant 60 mg once daily (QD). Sustained responses, based on predefined thresholds for reductions in monthly migraine days (MMDs) over a specified period, allow for evaluation of long-term efficacy of atogepant. The ELEVATE trial enrolled participants with episodic migraine who had inadequate response to two to four classes of conventional oral preventive medications; the PROGRESS trial enrolled participants with chronic migraine. These post-hoc analyses were conducted in the modified intent-to-treat (mITT) populations for the atogepant 60 mg QD group from the RCTs ELEVATE (151 participants) and PROGRESS (256 participants). An initial response was defined as ≥ 50%, ≥ 75%, or 100% reduction in MMDs from baseline to month 1 of each respective RCT. Proportions of participants who maintained or exceeded their month 1 response threshold through months 2 and 3 of each RCT were calculated. For the OLE, (ELEVATE, 240 participants and PROGRESS, 284 participants in the mITT population), initial response was defined as ≥ 50%, ≥ 75%, or 100% reduction in MMDs from baseline to month 4 of the OLE. Proportions of participants who maintained or exceeded their month 4 response threshold at month 12 of the OLE were calculated.
Results
In the two 12-week RCTs, 61.3% (49/80) of ELEVATE participants and 74.2% (69/93) of PROGRESS participants who experienced an initial ≥ 50% reduction in MMDs during month 1 of each RCT continued to have a ≥ 50% reduction in MMDs during both months 2 and 3. During the OLE, 83.4% (121/145) of participants from ELEVATE and 88.5% (131/148) of participants from PROGRESS who experienced a ≥ 50% reduction in MMDs from the RCT baseline to month 4 of the OLE continued to have a ≥ 50% reduction in MMDs at month 12 of the OLE. High rates of sustained responses were similarly observed across the other response thresholds.
Conclusions
Participants who experienced an initial clinically meaningful response with atogepant continued to experience sustained responses over the 3-month RCTs as well as at 12 months of their OLE study.
Trial registration
ELEVATE (3101-304-002), NCT04740827 ( https://clinicaltrials.gov/study/NCT04740827?cond = ELEVATE,%20NCT04740827&rank=1&tab = results ), 2021-02-05; PROGRESS (3101-303-002), NCT03855137 ( https://clinicaltrials.gov/study/NCT03855137?cond = PROGRESS,%20NCT03855137&rank=1&tab = results ); 2019-02-25; Open-label Extension (3101-312-002), NCT04686136 ( https://clinicaltrials.gov/study/NCT04686136?cond = NCT04686136&rank=1 ); 2021-02-19.
Förderung
- AbbVie
Zitieren
APA
Cho, S., Friedman, D. I., Chalermpalanupap, N., Nahas, S. J., Dabruzzo, B., Najib, U., Liu, Y., Carr, K., Sakai, F., Smith, J. H., & Pozo-Rosich, P. (2026). Sustained response to atogepant in episodic and chronic migraine: Post-hoc analyses of ELEVATE and PROGRESS, and their open-label extension. Cephalalgia, 46(11). https://doi.org/10.1177/03331024261499722
Vancouver
Cho S, Friedman DI, Chalermpalanupap N, Nahas SJ, Dabruzzo B, Najib U, et al. Sustained response to atogepant in episodic and chronic migraine: Post-hoc analyses of ELEVATE and PROGRESS, and their open-label extension. Cephalalgia. 2026;46(11). doi:10.1177/03331024261499722
BibTeX
@article{Cho2026,
author = {Cho, Soo-Jin and Friedman, Deborah I. and Chalermpalanupap, Natty and Nahas, Stephanie J. and Dabruzzo, Brett and Najib, Umer and Liu, Yingyi and Carr, Karen and Sakai, Fumihiko and Smith, Jonathan H. and Pozo-Rosich, Patricia},
title = {Sustained response to atogepant in episodic and chronic migraine: Post-hoc analyses of ELEVATE and PROGRESS, and their open-label extension},
journal = {Cephalalgia},
year = {2026},
volume = {46},
number = {11},
doi = {10.1177/03331024261499722}
}
EUVIMED